Tuesday 14 MayWednesday 15 MayThursday 16 May

Tuesday 14 May

 Opening of the Workshop
 4:00 PM

Opening Remarks
David Burger, PharmD, PhD - Radboud University Medical Centre, the Netherlands

  Session 1 - 20 Years in Review
Chairs: David Burger & David Back
 4:15 PM

Drug-drug interactions: all you need to know beyond
Marta Boffito, MD, PhD - Chelsea and Westminster Hospital, United Kingdom

 4:45 PM

Courtney Fletcher, PharmD

Stop measuring ARV levels in plasma!
Courtney Fletcher, PharmD - University of Nebraska, United States

 5:15 PM

Terrence Blaschke, MD

50% adherence is enough with modern ARVs, right?
Terrence Blaschke, MD - Stanford University, United States

 5:45 PM

Jonathan Schapiro, MD

Modern ARVs do not develop resistance, do they?
Jonathan Schapiro, MD - Sheba Medical Center, Israel

 6:15PMRound-Table Discussion 
 Welcome Reception + Group Photo 

Wednesday 15 May

 Session 2 - Novel strategies for prevention and therapy
Chairs: Andrea Calcagno & Kimberly Scarsi
 8:30 AM

The ‘third wave’ of TB drug development: what’s on the horizon (for patients with or without HIV)
Kelly Dooley, MD, PhD - Johns Hopkins University, United States

 Abstract-driven Presentations
 9:00 AM

Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine
Anthony Podany, PharmD - University of Nebraska Medical Center, United States

 9:15 AMIn silico design of a microarray patch as a multipurpose prevention technology
Rajith Rajoli - Univerisity Of Liverpool, United Kingdom

 9:30 AMPopulation pharmacokinetics of VRC01 in infants and adults
Jerry Li - University of California San Diego, United States
9:45 AMThe initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects
Samit Joshi, MD - ViiV Healthcare, United States
 10:00 AMDiscussion
10:15 AMMorning Coffee Break & Poster Session I (No. 19 - 36)
 Session 3 - Viral Hepatitis & Liver Disease
Chairs: Jennifer Kiser & Alice Tseng 
11:00 AM

Novel antiviral and immune targets to cure HBV
Fabien Zoulim, MD - INSERM, France

 11:30 AM

Pharmacological treatment of NASH
Sven Francque, MD, PhD - University Hospital Antwerp & University of Antwerp, Belgium

 Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare
Chair: Jonathan Schapiro


Opening Remarks
Jonathan Schapiro, MD - Sheba Medical Center, Israel

 12:00 PM

Improved long acting drug delivery: What are the technologies?
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom

 12:20 PM

Long acting HIV drugs for treatment: Data and potential implementation
Charles Flexner, MD - Johns Hopkins University, United States

 12:40 PM

Long Acting HIV Drugs for Prevention: Data and Potential implementation
Laura Waters, MD - Central & North West London NHS Trust, Mortimer Market Centre, United Kingdom

  Closing Remarks 
 1:00 PMLunch Break
 Session 4 - Drug-drug interactions: evolving challenges
Chairs: Saye Khoo & Angela Kashuba
 2:00 PM

Clinical Case Presentation
Catia Marzolini, PharmD, PhD - University Hospital Basel & University of Liverpool

 2:30 PM

ClinicalCasesDDI Website Launch
José Moltó, MD, PhD - Hospital Universitari Germans Trias i Pujol, Spain

 Abstract-driven Presentations
 2:40 PMChanges in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website
Sara Gibbons - University of Liverpool, United Kingdom
 2:55 PMDrugs abuse and chemsex: a new challenge for antiretroviral drug-drug interaction
Tess Martin - APHM La Timone, France
 3:10 PMEffect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy
Michelle Pham - University Of Nebraska Medical Center
 3:30 PMAfternoon Coffee Break & Poster Session II (No. 37 - 48)
 4:15 PMDebate: Dual maintenance for HIV: Why fix it if it's not broken?
Moderator: Jonathan Schapiro

Pro Perspective
José Ramón Arribas, MD - Hospital La Paz, IdiPaz, Spain


Con Perspective
Andrew Hill, MD - University of Liverpool, United Kingdom

 Special Lecture
 5:00 PMRegulatory perspective on evaluating ARVs in during pregnancy
Kimberly Struble, PharmD - US Food & Drug Administration, United States
 7:00 PM Networking Dinner 

Thursday 16 May

 Session 5 - Special populations and adherence
Chairs: Terrence Blaschke & Tim Cressey
 8:30 AMSpecial Presentation: Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)
Paul Domanico, PhD - Clinton Health Access Initiative, United States
 8:45 AMInfant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1
Laura Dickinson - University Of Liverpool, United Kingdom
 9:00 AMPharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum
Jeremiah Momper - University Of California San Diego, United States
 9:15 AMLow isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment
Marije Van Schalkwyk, MD - Stellenbosch University, South Africa
 9:30 AMPharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum
Kristina Brooks, PharmD - University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States
 9:45 AMTenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy
Jenna Yager - University of Colorado, United States
 10:00 AMAn exploration of adherence measures to detect recent changes in Truvada® dosing patterns
Daijha Anderson - University Of North Carolina Eshelman School Of Pharmacy, United States
 10:15 AMCoffee Break 
 11:00 AMShort Poster Presentations; "Best of Posters"
Moderator: Giovanni Di Perri & Marco Siccardi
 Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV
Felix Stader, University Hospital Basel, Switzerland
 Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy
Mary Gockenbach - US Food and Drug Administration, Division of Pediatrics and Maternal Health
 A semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescents
Bernard Ngara - University Of Zimbabwe College Of Health Sciences, Zimbabwe
 Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir
Aarti Patel - Glaxosmithkline R&D, United Kingdom
 The Next 20 Years
Chairs: Charles Flexner & David Burger
 11:30 AM

CRISPR/Cas and gene editing for HIV
Paula Cannon, PhD - University of Southern California Keck School of Medicine, United States

 12:00 PM

Owen, Andrew - 2019

Understanding the key determinants of performance for long-acting formulations
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom

 Closing Remarks

Jennifer Kiser, PharmD
University of Colorado Health Science Center, United States

 12:45 PMLunch